Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma
BOSTON – Lotte Biologics Co. has signed a deal to manufacture an antibody therapy for British biotech startup Ottimo Pharma as the South Korea...
Jollibee to buy chicken chain Norang Tongdak amid global K-food frenzy
Jollibee Foods Corp., a household name in Southeast Asia’s food market, has been named the preferred buyer of Norang Tongdak, a South Korean f...
Samsung Biologics to spin off biosimilar unit Samsung Bioepis
Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Deloitte Anjin to lead sale of Four Points by Sheraton Josun, Myeongdong
IGIS Asset Management Co., a leading South Korean real estate investment firm, has chosen Deloitte Anjin LLC as its lead manager to sell Four Points...
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
SillaJen: First to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
Chong Kun Dang to build new plant for foray into biologics market
Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Koramco REITS chosen preferred buyer of Crescendo Building in Seoul
Koramco REITs Management & Trust Co., a leading South Korean real estate firm, has been chosen as the preferred negotiator to buy the Crescendo ...
Lotte Biologics eyes first ADC CDMO order in 2025
SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...
Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut
SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...
SK Biopharmaceuticals, Eurofarma to set up AI epilepsy platform JV in US
South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...
Yuhan’s lung cancer drug gets OK in Europe
Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...
Boryung, Lotus Pharma signs CDMO deal on anticancer injection
South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...
SK Biopharm submits NDA of epilepsy drug to China
South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...
GIC to pick preferred bidder in $1.1 bn Seoul landmark building sale
Singapore’s GIC Private Ltd., the world’s sixth-largest sovereign wealth fund, is set to select a preferred bidder for the sale of a lan...
Korea Zinc, Hanwha to co-work on Austrailian BESS project
Korea Zinc Inc., the world’s top lead and zinc smelter, said on Tuesday its Australian subsidiary Ark Energy selected Hanwha Corp. as the pref...
Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug
Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...
Hanmi Pharma to move up launch of anti-obesity drug
South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...
Samsung Biologics wins $668 million CDMO deal with European pharma
Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...
Korean logistics companies expand overseas businesses
South Korea’s logistics companies such as local industry leader CJ Logistics Corp. are expanding their overseas operations to take advantage o...
Korea’s LIG Nex1 to export unmanned surface vessel
GUMI, North Gyeongsang Province — South Korean defense maker LIG Nex1 Co. aims to export its unmanned surface vessel (USV) under development a...
Apparel maker Hansae sets sights on auto parts business as growth driver
HO CHI MINH CITY – South Korean apparel maker Hansae Yes24 Group has set its sights on the auto parts business as a new growth driver to diver...
Celltrion's anti cancer drugs hold 90% market share in C.America
South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....
Korail to join Manila railway maintenance project
South Korea's state-run railway company Korea Railroad Corporation (Korail) said on Monday that it participates in the operation and maintenance (O&...
IMM consortium picked as preferred bidder for Ecorbit
A consortium of IMM Private Equity and IMM Investment has moved a step closer to owning South Korea’s No. 1 landfill company Ecorbit Co. after...
Hanwha’s Kim Dong-seon to raise his stake in Galleria to 19.86%
Kim Dong-seon, vice president of South Korea’s Hanwha Galleria Corp. and the third son of Hanwha Group Chairman Kim Seung-yeon, plans to buy a...
